Even in the world of Big Pharma, where pipelines of a dozen or more late-stage drugs are common, a couple of blockbuster-sized experimental programs can make a huge difference for the forward-looking analysts who cover these companies. Let’s use Merck as an example.

…read more

Source: Analysts cheer on Merck’s comeback campaign, pumping up blockbuster forecasts


0 No comments